ANI Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANIP research report →
Range $85 – $119
Price Chart
About the company
ANI Pharmaceuticals, Inc. , a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products.
- CEO
- Nikhil Lalwani
- IPO
- 2000
- Employees
- 970
- HQ
- Princeton, NJ, US
Get TickerSpark's AI analysis on ANIP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.56B
- P/E
- 13.35
- Fwd P/E
- 7.24
- PEG
- 0.07
- P/S
- 1.51
- P/B
- 2.30
- EV/EBITDA
- 5.35
- Div Yield
- 0.00%
- Gross Margin
- 67.76%
- Op Margin
- 17.26%
- Net Margin
- 11.22%
- ROE
- 20.00%
- ROIC
- 10.54%
Latest fiscal year · YoY change
- Revenue
- $883.37M+43.8%
- Gross Profit
- $450.64M+23.7%
- Op Income
- $81.23M
- Net Income
- $78.34M+522.9%
- EPS
- $3.50+436.5%
- OCF Growth
- +189.3%
- FCF Growth
- +220.6%
- 52W High
- $87.76
- 52W Low
- $67.14
- 50D MA
- $72.27
- 200D MA
- $76.80
- Beta
- 0.47
- RSI (14)
- 41
- Avg Volume
- 423.03K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
ANI delivered strong third-quarter growth and raised full-year guidance, but Cortrophin volume conversion lagged expectations, prompting a revenue reset while the company announced a $560 million all-cash bid for Aegidus Therapeutics.· November 5, 2026
- Q3 revenue rose to $290.8 million, up 28% year over year, and adjusted EBITDA increased 40% to $82.3 million.
- Adjusted non-GAAP EPS was $2.70 versus $2.04 a year ago; non-GAAP gross margin improved to 61.8%.
- Cortrophin revenue was $138.7 million, up 36% year over year, but full-year 2026 guidance was cut to $480 million-$500 million from $520 million-$540 million due to slower conversion in gout and specialty pharmacy bottlenecks.
- ILUVIEN revenue grew 34% to $22.3 million, and generics revenue increased 11% to $104.5 million.
- ANI raised 2026 total revenue, EBITDA, EPS, and gross margin guidance despite the Cortrophin reset, and announced an all-cash acquisition offer for Aegidus to add emcetate and rare-disease scale.
ANI reported third-quarter total net revenues of $290.8 million, up 28% year over year, with adjusted EBITDA of $82.3 million, up 40%. Adjusted non-GAAP diluted EPS was $2.70 versus $2.04 in the prior-year period. Non-GAAP gross margin was 61.8%, up about 260 basis points year over year, while non-GAAP cost of sales was $111 million, R&D was $12.3 million, and SG&A was $84.2 million. Segment-wise, Cortrophin Gel revenue was $138.7 million (+36%), ILUVIEN revenue was $22.3 million (+34%), generics revenue was $104.5 million (+11%), and Harmony-related revenue was $11.5 million. For 2026, ANI now expects total revenue of $1.085 billion-$1.125 billion, Cortrophin revenue of $480 million-$500 million, ILUVIEN revenue of $80 million-$85 million, adjusted EBITDA of $290 million-$300 million, adjusted gross margin of 60.3%-61%, and non-GAAP EPS of $9.37-$9.71.
Nikhil Lalwani framed the quarter as evidence that ANI’s three-priority strategy is working: scale rare disease, execute in generics, and allocate capital discipline. He emphasized that the core business remains strong, but Cortrophin’s gout rollout created a temporary conversion bottleneck rather than a demand problem, and he said the company remains confident in the product’s multiyear growth opportunity. He also positioned the Aegidus bid as consistent with ANI’s rare-disease strategy, saying emcetate expands the company’s footprint, pipeline, and long-term growth profile.
Stephen Carey highlighted solid profitability and cash generation, including $420.8 million of unrestricted cash at quarter-end, record operating cash flow of $83.8 million in Q3, and $198.8 million year to date. He noted $616.9 million of outstanding debt, gross leverage of 2.2x, and net leverage of 0.7x on trailing 12-month adjusted EBITDA of $283.2 million. He said ANI plans to fund the Aegidus deal with about $300 million of cash plus up to $300 million of debt via a committed bridge facility, and expects pro forma net leverage of about 2.7x at close. He also said the company repurchased 275,000 shares for $20 million year to date, at an average price of about $72.54.
Analysts focused first on whether Cortrophin’s revised guidance reflected a demand issue or mainly a revenue-conversion issue. Management said demand at the top of the funnel remains strong, with new gout cases initiated in the last five months about 85% higher than the prior five months, and said the missed guidance was driven by specialty pharmacy capacity and slower-than-expected onboarding of new primary-care and podiatry prescribers. On Aegidus, analysts asked about emcetate pricing, patient conversion from the 60-patient expanded access program, time to peak sales, and the path to identify more patients; ANI said it is not giving 2027 or peak-sales guidance yet, described the drug as a daily oral tablet for life-long use, and stressed disease education plus claims-based analytics to broaden diagnosis.
ANI showed strong underlying operating momentum: revenue, EBITDA, gross margin, and EPS all grew meaningfully year over year, and generics continued to outperform. Management said Cortrophin demand remains very strong and that early improvements in conversion are already appearing, while ILUVIEN and rare disease both posted solid growth. The Aegidus transaction gives ANI a commercial-stage ultra-rare asset with approved treatment, durable IP, and a launch base of more than 100 identified U.S. patients.
The main near-term risk is execution: Cortrophin’s growth story is being constrained by specialty pharmacy capacity and slower conversion in new prescriber channels, forcing a cut to full-year revenue guidance. Management also said the Aegidus deal will be dilutive to adjusted EPS in year 1 due to launch investment, and it is not providing 2027 or peak-sales guidance yet. The acquisition also adds leverage and depends on successful payer coverage, EAP-to-commercial conversion, and broader diagnosis growth to realize its value.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 87.9%
- Shares Outstanding
- 22.73M
- Float Shares
- 19.97M
of shares held by institutions
315 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 3.16M | ▲ 197.22K |
| Vanguard Group Inc | 1.31M | ▲ 27.60K |
| State Street Corp | 950.97K | ▲ 119.32K |
| American Century Companies Inc | 912.65K | ▲ 338.17K |
| Vanguard Capital Management LLC | 904.71K | ▲ 66.48K |
| Soleus Capital Management, L.P. | 867.76K | ▲ 47.52K |
| Dimensional Fund Advisors LP | 728.75K | ▲ 105.28K |
| Tang Capital Management LLC | 707.50K | 0 |
| Ubs Group AG | 621.34K | ▲ 323.80K |
| Geode Capital Management, LLC | 545.06K | ▲ 8.66K |
| Millennium Management LLC | 507.21K | ▼ 84.81K |
| Arrowstreet Capital, Limited Partnership | 491.83K | ▼ 70.18K |
Held by 333 ETFs
Biggest fund positions in ANIP by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Lalwani Nikhil | sell | 1,318 |
| Nov 18, 26 | Lalwani Nikhil | sell | 4,082 |
| Nov 13, 26 | Cook Meredith | sell | 500 |
| Oct 29, 26 | CAREY STEPHEN P. | sell | 2,850 |
| Oct 15, 26 | Lalwani Nikhil | sell | 5,400 |
| Oct 13, 26 | Cook Meredith | sell | 500 |
| Sep 29, 26 | CAREY STEPHEN P. | sell | 2,850 |
| Sep 15, 26 | Lalwani Nikhil | sell | 5,400 |
| Sep 11, 26 | Thoma Jeanne | sell | 1,000 |
| Sep 14, 26 | Cook Meredith | sell | 500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ANIP coverage
Recent articles, reports, and earnings notes.
No research on ANIP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ANIP report →ANI Pharmaceuticals to Present at Upcoming December Investor Conference
globenewswire.com · Nov 19
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Value Stock
zacks.com · Nov 17
ANI Pharmaceuticals, Inc. $ANIP Stock Acquired by Aberdeen Group plc
defenseworld.net · Nov 17
ANI Pharmaceuticals, Inc. (ANIP) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 7
ANI Pharmaceuticals Q3 Earnings Call Highlights
marketbeat.com · Nov 5
ANI (ANIP) Reports Q3 Earnings: What Key Metrics Have to Say
zacks.com · Nov 5
ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue Estimates
zacks.com · Nov 5
ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.